# Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

> **NCT05601700** · PHASE3 · RECRUITING · sponsor: **Ente Ospedaliero Ospedali Galliera** · enrollment: 132 (estimated)

## Conditions studied

- Carcinoma, Ovarian Epithelial
- Low Grade Serous Adenocarcinoma of Ovary

## Interventions

- **DRUG:** Letrozole tablets
- **DRUG:** carboplatin AUC 5 and paclitaxel 175 mg/m2

## Key facts

- **NCT ID:** NCT05601700
- **Lead sponsor:** Ente Ospedaliero Ospedali Galliera
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-22
- **Primary completion:** 2029-09-22
- **Final completion:** 2029-09-22
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2025-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05601700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05601700, "Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05601700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*